Klerimed

Clarithromycin, the active ingredient in Klerimed, is a macrolide antibiotic presented as an oral dosage form for systemic use. It is employed to treat a range of bacterial infections, particularly in adult and pediatric patients where a macrolide is indicated. The drug targets susceptible Gram‑positive and some Gram‑negative organisms, offering an alternative to penicillin‑based regimens.

GNH USA supplies Klerimed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance.

Clarithromycin is used to treat bacterial infections affecting the respiratory tract, sinuses, skin and gastrointestinal system. - Community‑acquired pneumonia: reduces bacterial load and improves clinical recovery in adults and children. - Acute bacterial sinusitis: alleviates sinus inflammation and clears infection caused by susceptible organisms. - Acute bacterial bronchitis: shortens duration of cough and resolves bronchial infection. - Skin and soft tissue infections: eradicates susceptible Staphylococcus and Streptococcus species in cellulitis and wound infections. - Helicobacter pylori eradication regimens: contributes to bacterial eradication when combined with other agents in approved triple or quadruple therapy.

Clarithromycin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, occasionally watery. - Abdominal pain: cramping or discomfort in the abdomen. - Taste disturbance: altered or metallic taste sensation. - Headache: mild headache episodes.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - QT prolongation: cardiac rhythm changes that may lead to arrhythmia. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Clostridioides difficile colitis: severe diarrhea due to intestinal flora disruption.

When prescribing clarithromycin, clinicians should consider several precautionary measures to ensure safe use. - Assess liver function: avoid use in patients with severe hepatic impairment. - Monitor cardiac status: caution in patients with known QT prolongation or electrolyte disturbances. - Review drug history: avoid concurrent use with strong CYP3A4 inhibitors. - Adjust for renal impairment: dose may need modification in severe renal dysfunction. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Clarithromycin interacts with several medicines through metabolic pathways and additive pharmacodynamic effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase clarithromycin levels and toxicity. - Certain antiarrhythmics (e.g., amiodarone, sotalol): risk of severe QT prolongation. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): heightened risk of myopathy.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Theophylline: clarithromycin can raise plasma concentrations, monitor for toxicity. - Carbamazepine: may reduce clarithromycin efficacy and increase carbamazepine levels.